Previous 10 | Next 10 |
-- Proceeds from Offering Will Be Used to Refinance Existing 4.375% Senior Unsecured Notes Due 2025 -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes ...
Hologic (NASDAQ: HOLX ) jumps 7% premarket on light volume in reaction to its upward revision of Q4 guidance driven by strong sales of COVID-19 tests and Panther instruments. More news on: Hologic, Inc., Stocks on the move, Healthcare stocks news, , Read more ...
As the pandemic grinds on, companies that make diagnostic tests for SARS-CoV-2 are working overtime to meet immense demand and invent superior products. Though there are several different types of coronavirus tests, and a handful of different business models that operate in the wider medical dia...
This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Larry Robbins' Glenview Capital Management Portfolio artic...
In this episode of Industry Focus: Wildcard , Dylan Lewis chats with Motley Fool analyst Brian Feroldi about a company with a very promising and disruptive technology. Learn about their business model, who their main competitors are, and what gives them a competitive edge. Discover what the b...
Shares of Quidel (NASDAQ: QDEL) were down a whopping 27% at 2:27 p.m. EDT on Thursday after rival Abbott Laboratories (NYSE: ABT) gained emergency use authorization from the Food and Drug Administration for its 15-minute, $5 test for the novel coronavirus. Fellow test makers Hologic ...
COVID-19 test and equipment makers are slipping premarket - and Abbott Laboratories (NYSE: ABT ) is up 9.5% , setting it its best day in months - following last evening's FDA approval of Abbott's quick, inexpensive test for the disease . More news on: Abbott Laboratories, Quidel Corpor...
Although the coronavirus crisis is far from over, it has already transformed the way healthcare players operate. Some companies have seen record demand for their essential medicines, while others have only recently seen their revenues rebound after shutdowns and stay-at-home orders wreaked havo...
Hologix (NASDAQ: HOLX ) has acquired privately held Acessa Health , a developer of a minimally invasive procedure to treat uterine fibroids, for $80M in cash plus sales growth earnouts. More news on: Hologic, Inc., Healthcare stocks news, Merger & acquisition news, Read more ....
-- Transaction Strengthens Hologic’s GYN Surgical Portfolio with Highly Complementary, Clinically Differentiated New Treatment – Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Acessa Health Inc., a privately-held innova...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...